Skip to main content
. Author manuscript; available in PMC: 2006 Jul 11.
Published in final edited form as: Endocrinology. 2001 Mar;142(3):1167–1178. doi: 10.1210/endo.142.3.8021

FIG. 8.

FIG. 8

The MAP kinase inhibitor PD98059 releases the PMA-induced block on cAMP activation of Dmrt1. Analysis of Dmrt1, c-fos, and actin mRNA levels in Sertoli cells treated with PMA, cAMP, and the MEK1/2 inhibitor PD98059. Sertoli cells were cultured as described in the material and methods either without any added treatment (None), in the presence of 8-bromo-cAMP, in the presence of PMA, in the presence of the MEK1/2 inhibitor PD98059 (PD) or in the presence of a combination of each of these treatments. Cells were cultured for either 1 or 4 h with each treatment. RNase protection assays were used to examine mRNA levels for Dmrt1 (A) and c-fos (B). Actin mRNA was measured to control for general RNA changes and sample loading. Arrows mark the protected fragments and tRNA represents the negative control.